Navigating the Future: Atherosclerosis Drugs Market Trends and Forecast Insights, 2025 Edition

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Atherosclerosis Drugs Market Size Growth Forecast: What to Expect by 2025?
The market size of atherosclerosis drugs has been on a consistent growth trajectory in the past few years. The prediction is that it will expand from $49.89 billion in 2024 to reach $51.42 billion in 2025, registering a Compound Annual Growth Rate (CAGR) of 3.1%. This growth during the historical period can be credited to factors like cholesterol management, blood pressure control, initiatives to stop smoking, as well as research and development, and advances in diagnostics.

How Will the Atherosclerosis Drugs Market Size Evolve and Grow by 2029?
A steady expansion is anticipated in the atherosclerosis drugs market over the coming years, with a projection to reach $59.38 billion in 2029, growing at a compound annual growth rate (CAGR) of 3.7%. The predicted growth during the forecast period can be credited to the emergence of novel therapies, advancements in precision medicine, immunotherapy, inflammation techniques, innovative lipid management strategies and regulatory backing. The forecast period is expected to witness significant trends such as biologic therapies, gene manipulation and treatment, combined therapy methods, individualized treatment plans, telehealth services and remote patient monitoring.

View the full report here:
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

What Drivers Are Propelling the Growth of Atherosclerosis Drugs Market Forward?
The anticipated surge in cardiovascular diseases is projected to accelerate the growth of the atherosclerosis drug market. Cardiovascular diseases encompass all heart and blood vessel related diseases, and atherosclerosis is the condition characterized by the accumulation of elements such as fats, cholesterol, and other substances on the arterial walls of a person. It contributes massively to cardiovascular diseases like coronary heart disease and stroke. Atherosclerosis medication provides treatment for cardiovascular diseases by managing risk factors and underlying conditions, which include elevated cholesterol levels and blood clot formation, among others. For instance, data from the Minnesota Department of Health (a US-based state health agency) in September 2024 revealed that approximately 30% of Minnesota adults, amounting to nearly 1.4 million people, experienced high blood pressure in 2023. Moreover, in 2022, hypertensive diseases were the influential or contributing cause of death for 14,225 residents, making up approximately 28% of all deaths in the state. Consequently, the widespread occurrence of cardiovascular diseases will stimulate the atherosclerosis drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp

Which Emerging Trends Are Transforming the Atherosclerosis Drugs Market in 2025?
A leading trend observed in the atherosclerosis drugs market is the emphasis on product innovation. Major companies in this market are enhancing their position by creating innovative medicines and securing regulatory approval for them. For example, Novo Nordisk A/S, a Danish healthcare firm, declared in March 2024 that it had received approval for Wegovy (semaglutide), targeted at reducing cardiovascular risk in individuals who are overweight or obese. This is the pioneer weight loss drug certified to mitigate the risk of critical cardiovascular events in adults with obesity or overweight who also have pre-existing cardiovascular disease. It introduces a novel treatment solution for this vulnerable group. The dual role of this medication not only tackles obesity management, but also acts as a preventive measure against severe cardiovascular issues, potentially enhancing patient prognosis and extending their lives.

What Are the Key Segments in the Atherosclerosis Drugs Market?
The atherosclerosis drugs market covered in this report is segmented -

1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:
1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor
2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements
3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril
4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics
5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants
6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol
7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil
8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12621&type=smp

Who Are the Key Players Shaping the Atherosclerosis Drugs Market's Competitive Landscape?
Major companies operating in the atherosclerosis drugs market include Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc.

What Geographic Markets Are Powering Growth in the Atherosclerosis Drugs Market?
North America was the largest region in the atherosclerosis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12621

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.